Europe Cell Lysis And Disruption Market Size & Outlook
Europe cell lysis and disruption market, 2018-2028 (US$M)
Related Markets
Europe cell lysis and disruption market highlights
- The Europe cell lysis and disruption market generated a revenue of USD 1,158.4 million in 2020.
- The market is expected to grow at a CAGR of 9.7% from 2021 to 2028.
- In terms of segment, reagent-based was the largest revenue generating technique in 2020.
- Reagent-based is the most lucrative technique segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2021 to 2028.
Europe data book summary
| Market revenue in 2020 | USD 1,158.4 million |
| Market revenue in 2028 | USD 2,425.1 million |
| Growth rate | 9.7% (CAGR from 2020 to 2028) |
| Largest segment | Reagent-based |
| Fastest growing segment | Reagent-based |
| Historical data covered | 2018 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Reagent-based, Physical Disruption |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.3% of the global cell lysis and disruption market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,195.9 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Lysis And Disruption Market Scope
Cell Lysis And Disruption Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe cell lysis and disruption market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 61.74% in 2020. Horizon Databook has segmented the Europe cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
The European cell lysis & disruption market is expected to grow at a steady rate throughout the forecast period at a CAGR of 9.68%. This is majorly due to support received from government and nongovernment organizations for R&D and commercial production of bio therapeutics.
Major European countries considered within the marketspace include the UK and Germany. However, other European countries that hold a strong position in the region include France, Sweden, Switzerland, Norway, Denmark, Italy, Austria, and the Netherlands.
Denmark and Norway have increased the uptake of infliximab biosimilars owing to the presence of a tender system to pay for the medicines in the country. Furthermore, presence of national and international organizations, such as the European Union.
Reasons to subscribe to Europe cell lysis and disruption market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe cell lysis and disruption market databook
-
Our clientele includes a mix of cell lysis and disruption market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cell lysis and disruption market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Europe cell lysis and disruption market size, by country, 2018-2028 (US$M)
Europe Cell Lysis And Disruption Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
